iLASIK | LASIK Cornwall| Premium Vision Surgical Centre

The iLASIK Procedure

= iDesign + iFS + VISX S4IR

The iLASIK procedure (using exclusive technology, only from Abbott) takes only minutes. It reshapes your cornea to correct the refractive imperfections in your eye (these imperfections are essentially the reason why near or far images could be distorted and blurry). And when you have the iLASIK procedure, each step of your treatment will be completely integrated and fully personalized, utilizing advanced vision correction technology.

Laser Vision Correction That’s Truly Personalized

There has never been a laser vision correction procedure that offers the precision and accuracy of the Advanced CustomVue Procedure. Since 2003, the Advanced CustomVue Procedure has continued to earn FDA approvals to treat the broadest range of vision imperfections possible, including mild to severe nearsightedness, farsightedness and all types of astigmatism.

 An Individualized Treatment

The Advanced CustomVue Procedure begins with an individual vision evaluation using our iDesign System which creates a map of your eyes’ unique imperfections. The Advanced CustomVue Procedure uses the digital information from that map to design a custom treatment for each of your eyes. This iDesign map information is then transferred to the STAR S4 IR Excimer Laser. The laser uses this information to apply a cool laser beam that reshapes your cornea to create a new curvature and correct your vision.

idesign-clinica-balstro-advanced-wavescan-studio

 iDesign_0

Step One: Creating your personalized vision profile

The first step in the iLASIK procedure is to perform a wavefront diagnosis using the WaveScan WaveFront system. Your eye is unique—as personal as your fingerprint or your DNA. The WaveScan WaveFront system creates a 3-D map that provides detailed information of your vision correction requirements to develop a personalized laser vision correction plan.

The Advanced CustomVue procedure, will be Powered by iDesign giving you a truly innovative approach to measuring refractive errors that will drive treatment design. The unique combination of iDesign and STAR S4 IR Excimer Laser systems is Innovation Built on Proven Technology. It enhanced patient throughput and ease of use and enables the potential to capture highly aberrated eyes. Five measurements within a single capture sequence High-definition sensor maximizes capture rates

  1. Pupillometry
  2. Keratometry
  3. Wavefront Aberrometry
  4. Auto-Refraction
  5. Topography

This is how iDesign measures your eyes

These are the captured maps that will be corrected with the laser

Step Two: making the lasik flap

The iLASIK procedure EXCLUSIVELY uses a process called the IntraLase method to create a personalized thin LASIK flap that is folded back in preparation to gently reshape the cornea. Studies have shown that flaps created with the IntraLase method have fewer complications and greater stability than flaps created with a blade.1-3 Eighty-one percent of patients choose bladeless LASIK over traditional LASIK with a blade when given the choice.

Step Three: delivering the personalized iLASIK correction

Once the LASIK flap has been made, a second, ultra-precise “cool” laser is used to gently reshape the cornea to the desired curvature, based on the digital information from your personalized WaveScan WaveFront map. With your laser vision correction made, your doctor will reposition the LASIK flap, and your iLASIK procedure is complete. Many people sit up and immediately notice dramatically better vision.

Outstanding Results

Clinical studies presented to the FDA show that the Advanced CustomVue Procedure can potentially produce better vision than is possible with glasses or contact lenses.* In fact, clinical studies have shown that more patients were satisfied or very satisfied with their vision after the Advanced CustomVue Procedure than they were before with glasses or contact lenses.*

Other notable outcomes for specific indications show:*

Ninety eight percent of mild to moderate nearsighted patients could see 20/20 or better one year after treatment
One hundred percent of mild to moderate nearsighted patients could pass a driving test without glasses or contact lenses one year after treatment

*Data on file. AMO Development, LLC. CustomVue Procedure clinical trials submitted to the FDA; 2003, 2004, 2005 & 2007.

A walkthrough the process of ACV laser vision correction

Custom Laser Vision Correction (CustomVue)

Can we achieve supervision?

Custom LVC (ASA/PRK/LASIK) surgery, also known as wavefront LVC or wavefront-guided LVC, uses 3-dimensional measurements of how your eye processes images to guide the laser in re-shaping the front part of the eye (cornea). With a wavefront measurement system, some extremely precise, individualized vision correction outcomes may be achieved that would be impossible with traditional LVC surgery, contact lenses or eyeglasses. *** With custom LVC, your eye’s ability to focus light rays is measured, and a 3-D map used in wavefront technology is created that demonstrates irregularities in the way your eye processes images. Information contained in the map guides the laser in customizing the treatment to reshape your eye’s corneal surface so that these irregularities can be corrected.

Standard prescriptions for glasses, contacts or traditional LVC procedures can correct ordinary vision defects such as myopia, hyperopia, and astigmatism. But other irregularities associated with the eye’s optical system could not be addressed until the advent of wavefront and related technology used in custom LVC.*** Potential Benefits of Wavefront-Guided Custom LVC

Wavefront technology is groundbreaking because it has the potential to improve not only how much you can see, visual acuity measured by the standard 20/20 eye chart, but also how well you can see, in terms of contrast sensitivity and fine detail.

This translates into a reduced risk of post-LVC complications, such as glare, halos and difficulty with night vision.

How much you see depends on vision defects known as lower-order aberrations associated with common refractive errors including myopia, hyperopia and astigmatism, which traditional LVC can treat.*** How well you see can depend on presence of the type and numbers of visual distortions known as higher-order aberrations, which are optical defects other than common refractive errors.

Higher-order aberrations can create problems such as decreased contrast sensitivity or night vision, glare, shadows and halos. However, higher-order aberrations do not always affect vision. Unlike traditional LVC, custom LVC treats both lower- and higher-order aberrations. Custom LVC’s advantage lies in the area of quality of vision:

  • Greater chance of achieving 20/20 vision
  • Greater chance of achieving better than 20/20 vision
  • Reduced chance of losing best-corrected vision
  • Reduced chance of losing visual quality or contrast sensitivity
  • Reduced chance of night-vision disturbances and glare

Potential also exists for custom LVC to treat people who have lost best-corrected vision from any past refractive surgery: LVC, PRK, RK, etc.

LVC surgery

Wavefront LVC creates a highly individualized laser correction of your eye’s surface, guided by precise analysis of vision errors that occur as light rays travel through your eye.

“Sometimes patients complain about vision quality problems, such as not being able to see in dim or low light. This is referred to as poor contrast sensitivity,” said Roger Steinert, MD, vice chair of clinical ophthalmology and professor at University of California Irvine.

“Prior to the advent of wavefront measurements, there wasn’t anything we could do to measure or treat higher-order aberrations,” Steinert said. “With this technology breakthrough, we can now measure these disorders, show the patient what’s going on in their eye, link that information to the laser, and actually correct higher-order aberrations that diminish contrast sensitivity. Wavefront technology enables the surgeon to improve overall vision quality better than in the past.”

Wavefront-Guided LVC & Contrast Sensitivity

While visual outcomes as noted on familiar eye charts can be similar for wavefront-guided and conventional LVC, research has linked wavefront-guided procedures to better results in areas such as improved contrast sensitivity. A study reported in June 2009* found that 84 percent of 324 eyes that underwent wavefront-guided LVC procedures for myopia with or without astigmatism achieved 20/20 uncorrected vision or better. In specific tests measuring contrast sensitivity and night vision, significant improvement was noted. Custom LVC was found to induce certain types of aberrations, which did not appear to affect good visual outcomes.*** In certain cases, outcomes such as improved night vision with use of wavefront-guided LVC appear to surpass results that can be achieved with conventional LVC.

In August 2004, the U.S. Navy announced that patients at its refractive surgery center were achieving better distance vision and night vision after custom LVC than after traditional LVC.

In a small study, 88 percent of contrast sensitivity measurements improved after wavefront-guided LVC, while only 40 percent improved after regular LVC. This was one month after surgery.

Uncorrected visual acuity of 20/20 or better was achieved by similar numbers, however: 72 percent of the wavefront group and 70 percent of the regular LVC group. The study was published in the March 2004 issue of Ophthalmology, the clinical journal of the American Academy of Ophthalmology. — L.S.

How Custom LVC Works

The process for determining a custom LVC treatment begins with the use of a wavefront device to transmit a safe ray of light into your eye (iDesign). The light is then reflected back off the retina, out through the pupil, and into the device, where the reflected wave of light is received and arranged into a unique pattern that captures your lower- and higher-order aberrations.

All of these visual irregularities are then displayed as a 3-D map, referred to as a wavefront map. This information is then electronically transferred to the laser (in wavefront-guided systems), and computer-matched to the eye’s position, enabling the surgeon to customize the LVC procedure laser treatment (or “ablation”) to your unique visual requirements.

IMPORTANT PATIENT SAFETY INFORMATION

Please read the following information carefully.

Wavefront-Guided LASIK for Correction of Myopic Astigmatism, Hyperopic Astigmatism and Mixed Astigmatism (CustomVue LASIK Laser Treatment)

Statements regarding the potential benefits of wavefront-guided LASIK (CustomVue) are based upon the results of clinical trials. These results are indicative of not only the CustomVue treatment but also the care of the clinical physicians, the control of the surgical environment by those physicians, the clinical trials’ treatment parameters, and the clinical trials’ patient inclusion and exclusion criteria. Although many clinical trial patients after the CustomVue procedure saw 20/20 or better and/or had or reported having better vision during the day and at night, compared to their vision with glasses or contact lenses before the procedure, your results may vary. You can find information about the clinical trials below and in the CustomVue Patient Information Booklet. Only an eye care professional trained in laser vision correction can determine whether you are a suitable candidate for the CustomVue procedure. As with any surgical procedure, there are risks associated with the CustomVue treatment. Before deciding whether to have the CustomVue procedure, you should ask your doctor for and carefully review the CustomVue Patient Information Booklet. It is important to discuss the risks associated with the procedure and any questions you may have about the procedure with your doctor.

WAVEFRONT-GUIDED LASIK INDICATIONS AND INTENDED USES (LOW TO MODERATE MYOPIC ASTIGMATISM):

The STAR S4 excimer laser system and WaveScan WaveFront system are approved to perform wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of low to moderate myopic astigmatism up to -6.00 D MRSE, with cylinder between 0.00 and -3.00 D, in patients 21 years of age or older; and in patients with documented evidence of a change in manifest refraction of no more than 0.50 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is “STAR S4 ActiveTrak excimer laser system for wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments of myopic astigmatism up to -6.00 D MRSE, with cylinder between 0.00 and -3.00 D.” An acceptable alternate version of this official name is “wavefront-guided LASIK for correction of myopic astigmatism.”

Wavefront-guided LASIK is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application is based on a clinical trial of 351 eyes (189 primary and 162 secondary). Of all eyes treated, 318 were evaluated for effectiveness with 98.8% accountability at 3 months, 277 eyes with 96.9% accountability at 6 months, 102 eyes with 95.3% accountability at 9 months, and 86 eyes with 95.6% accountability at 12 months. The studies found that, of the 277 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 6 months, 100% were corrected to 20/40 or better, and 95.8% were corrected to 20/20 or better, in 71 spherical myopia eyes; and 99.5% were corrected to 20/40 or better, and 93.2% were corrected to 20/20 or better, in 206 astigmatic myopia eyes.

The study showed that at the 3-month stability time point, there was a loss of ≥2 lines of best corrected vision that can be obtained with spectacles in 1 of 239 astigmatic myopia eyes and there was no loss of ≥2 lines of best corrected vision in 79 spherical myopia eyes; there was 1 of 239 astigmatic myopia eyes with best spectacle corrected visual acuity (BSCVA) worse than 20/25 and none in 79 spherical myopia eyes with BSCVA worse than 20/25. During the course of study, no eye lost >2 lines of BSCVA and no eye had a BSCVA worse than 20/40.

WAVEFRONT-GUIDED LASIK INDICATIONS AND INTENDED USES (HIGH MYOPIC ASTIGMATISM):

The STAR S4 IR excimer laser system with VSS and WaveScan WaveFront system are approved to perform wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of high myopic astigmatism from -6.00 D to -11.00 D MRSE, with cylinder between 0.00 and -3.00 D, in patients 21 years of age or older; and in patients with documented evidence of a change in manifest refraction of no more than 1.00 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is “STAR S4 IR excimer laser system for wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments of myopic astigmatism from -6.00 to -11.00 D MRSE, with cylinder between 0.00 and -3.00 D.” An acceptable alternate version of this official name is “wavefront-guided LASIK for correction of high myopia with or without astigmatism.”

Wavefront-guided LASIK for correction of high myopic astigmatism is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application is based on a clinical trial of 184 eyes. Of all eyes treated, 180 were evaluated for effectiveness with 97.8% accountability at 3 months, 178 eyes with 96.7% accountability at 6 months, 170 eyes with 96.5% accountability at 9 months, and 107 eyes with 93.9% accountability at 12 months. The studies found that, of the 178 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 6 months, 98.3% were corrected to 20/40 or better, 97.2% were corrected to 20/32 or better, and 84.3% were corrected to 20/20 or better, without spectacles or contact lenses. The study showed that of 83 spherical and 101 astigmatic eyes, no eyes lost 2 or more lines of best corrected vision that can be obtained with spectacles (BSCVA), and none of the eyes had BSCVA worse than 20/40.

WAVEFRONT-GUIDED LASIK INDICATIONS AND INTENDED USES (HYPEROPIC ASTIGMATISM):

The STAR S4 excimer laser system and WaveScan WaveFront system are approved to perform wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of hyperopic astigmatism up to +3.00 D MRSE, with cylinder between 0.00 and +2.00 D, in patients 21 years of age or older; and in patients with documented evidence of a change in manifest refraction of no more than 1.0 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is “STAR S4 ActiveTrak excimer laser system for wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments of hyperopic astigmatism up to +3.00 D MRSE, with cylinder between 0.00 and +2.00 D.” An acceptable alternate version of this official name is “wavefront-guided LASIK for correction of hyperopic astigmatism.”

Wavefront-guided LASIK for hyperopic astigmatism is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application was based on a clinical trial of 144 eyes (74 primary and 70 secondary). Of all eyes treated, 134 were evaluated for effectiveness with 98.5% accountability at 3 months, 131 eyes with 97.0% accountability at 6 months, 118 eyes with 90.8% accountability at 9 months, and 27 eyes with 87.1% accountability at 12 months. The studies found that, of the 131 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 6 months, 97.3% were corrected to 20/40 or better, and 66.2% were corrected to 20/20 or better, in 74 spherical hyperopia eyes; and 93.0% were corrected to 20/40 or better, and 56.1% were corrected to 20/20 or better, in 57 astigmatic hyperopia eyes.

The study showed that, at the 6-month stability time point, there was no loss of ≥2 lines of best corrected vision that can be obtained with spectacles in 1 of 239 astigmatic myopia eyes, and there was no loss of ≥2 lines of best corrected vision that can be obtained with spectacles in either 63 astigmatic hyperopia eyes or 74 spherical hyperopia eyes; none of the 63 astigmatic hyperopia or 74 spherical hyperopia eyes had best spectacle corrected visual acuity (BSCVA) worse than 20/25. During the course of the study, one in 63 eyes with astigmatic hyperopia lost >2 lines of BSCVA at 1 month, no eyes with spherical hyperopia lost >2 lines of BSCVA, and no eye had a BSCVA worse than 20/40.

WAVEFRONT-GUIDED INDICATIONS AND INTENDED USES (MIXED ASTIGMATISM):

The STAR S4 IR excimer laser system with VSS and WaveScan WaveFront system are approved to perform wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments for the reduction or elimination of naturally occurring mixed astigmatism when the magnitude of cylinder (from 1.0 to 5.0 D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs; and in patients 21 years of age or older with documented evidence of a change in manifest refraction of no more than 0.50 D (in both cylinder and sphere components) for at least one year prior to the date of preoperative examination. Note that the complete name for this ophthalmic laser is “STAR S4 IR excimer laser system” for wavefront-guided laser-assisted in-situ keratomileusis (LASIK) treatments of naturally occurring mixed astigmatism when the magnitude of cylinder (from 1.0 to 5.0 D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs. An acceptable alternate version of this official name is “wavefront-guided LASIK for correction of mixed astigmatism.”

Wavefront-guided LASIK for mixed astigmatism is an elective procedure with the alternatives including but not limited to eyeglasses, contact lenses, photorefractive keratectomy (PRK), conventional LASIK, and other refractive surgeries. Approval of the application is based on a clinical trial of 86 eyes. Of all eyes treated, 86 were evaluated for effectiveness with 100.0% accountability at 3 months, 80 eyes with 95.2% accountability at 6 months, 69 eyes with 86.3% accountability at 9 months, and 63 eyes with 94.0% accountability at 12 months. The studies found that, of the 86 eyes eligible for the uncorrected visual acuity (UCVA) analysis of effectiveness at 3 months, 95.3% were corrected to 20/40 or better, 91.9% were corrected to 20/32 or better, and 61.6% were corrected to 20/20 or better, without spectacles or contact lenses.

The study showed that, of 86 astigmatic eyes, one eye temporarily lost 2 lines of best corrected vision that can be obtained with spectacles at 1 month and at 6 months, and none of the eyes had best spectacle corrected visual acuity (BSCVA) worse than 20/40.

CONTRAINDICATIONS:

Wavefront-guided LASIK is contraindicated in patients with collagen vascular, autoimmune or immunodeficiency disease, signs of keratoconus or abnormal corneal topography, patients taking Isotretinoin (Accutane®) or Amiodarone hydrochloride (Cordarone®) or who are pregnant or nursing.

WARNINGS:

Wavefront-guided LASIK is not recommended in patients who have diabetes, a history of Herpes simplex or Herpes Zoster keratitis, significant dry eye that is unresponsive to treatment, or severe allergies. For the treatment of low to moderate myopic astigmatism, lower uncorrected visual acuity may be anticipated in the treatment of higher degrees of myopia with and without astigmatism (≥5.0 D MRSE).

PRECAUTIONS:

Long-term risks of wavefront-guided LASIK beyond 12 months have not been studied. The safety and effectiveness of wavefront-guided LASIK surgery has ONLY been established with an optical zone of 6 mm and an ablation zone of 8 mm for myopic treatments, and an ablation zone of 9 mm for hyperopic and mixed astigmatism treatments. The safety and effectiveness of STAR S4 excimer laser system have NOT been established for wavefront-guided surgery in patients with low to moderate myopic astigmatism: whose WaveScan wavefront diameter is less than 6 mm; for treatments greater than -6 diopters of MRSE or with greater than 3 diopters of astigmatism and for retreatment with CustomVue LASIK. The safety and effectiveness of STAR S4 excimer laser system have NOT been established for wavefront-guided surgery in patients with high myopic astigmatism: whose WaveScan wavefront diameter is less than 5 mm; for treatments greater than -11 diopters of MRSE or with greater than 3 diopters of astigmatism. The safety and effectiveness of STAR S4 excimer laser system have NOT been established for wavefront-guided surgery in patients with hyperopic astigmatism: whose WaveScan wavefront diameter is less than 5 mm; for treatments greater than +3 diopters of MRSE or with greater than 2 diopters of astigmatism and for retreatment with CustomVue LASIK. The safety and effectiveness of the STAR S4 IR excimer laser system have NOT been established for wavefront-guided surgery in patients with mixed astigmatism: whose WaveScan wavefront diameter is less than 5.00 mm; for treatments greater than 5.00 D or less than 1.00 D of astigmatism and for retreatment with CustomVue LASIK.

Although the WaveScan WaveFront system measures the refractive error and wavefront aberrations of the human eyes—including myopia, hyperopia, astigmatism, coma, spherical aberration, trefoil, and other higher-order aberrations through sixth order—in the clinical studies for low to moderate myopic astigmatism, hyperopic astigmatism and mixed astigmatism, the average higher-order aberration did not decrease after CustomVue treatment. In the clinical studies for high myopic astigmatism, the average higher-order aberration increased after CustomVue treatment.

It is possible, after wavefront-guided LASIK treatment, that patients will find it more difficult than usual to see in conditions such as very dim light, rain, snow, fog, or glare from bright lights at night. Visual performance possibly could be worsened by large pupil sizes or decentered pupils. Pupil size should be evaluated under mesopic illumination conditions.

ADVERSE EVENTS AND COMPLICATIONS (LOW TO MODERATE MYOPIC ASTIGMATISM):

The clinical trial showed that the following adverse events or complications occurred in at least 1% of the 351 eyes at any interval up to 6 months post treatment: inflammation of the cornea under the flap (1.4%); double or ghost images (1.4%); and scratch on the surface of the eye (1.4%).

The following subjective symptoms frequency-rated “often or always” were increased in the effectiveness cohort at 6 months post treatment on 258 eyes compared with pretreatment on 332 eyes: dryness (9% vs. 6%); fluctuation of vision (3% vs. 2%); glare (4% vs. 2%); and halos (7% vs. 5%).

ADVERSE EVENTS AND COMPLICATIONS (HIGH MYOPIC ASTIGMATISM):

The clinical trial showed that the following adverse events or complications occurred in at least 1% of the 184 eyes at one or more postoperative examinations up to 6 months post treatment: cells growing under the flap (1.1%); scratch on the surface of the eye at 1 month or later (2.2%); swelling of the corneal between 1 week and 1 month postoperatively (2.7%); and double vision (or “ghost images”) in the operative eye (6.0%).

The following subjective symptoms were reported as present “often or always” by a higher percentage of subjects 6 months after treatment than before treatment: dryness (10.8% vs. 9.3%); halos (21.6% vs. 15.4%); and ghosting or shadowing of images (2.8% vs. 1.1%).

ADVERSE EVENTS AND COMPLICATIONS (HYPEROPIC ASTIGMATISM):

The clinical trial showed that the following adverse events or complications occurred in at least 1% of the 144 eyes at any interval up to 6 months post treatment: cells growing under the flap (2.1%); feeling of something in the eye (1.4%); double or ghost images (11.3%); and scratch on the surface of the eye (2.1%).

The following subjective symptoms rated “often or always” were increased in frequency in the effectiveness cohort at 6 months post treatment on 131 eyes compared with pretreatment on 136 eyes: dryness (17% vs. 6%); blurry vision (10% vs. 7%); fluctuation of vision (14% vs. 6%); halos (10% vs. 5%); and double or ghost images (7% vs. 3%).

ADVERSE EVENTS AND COMPLICATIONS (MIXED ASTIGMATISM):

The clinical trials showed that the following adverse events or complications occurred in at least 1% of the 86 eyes at one or more postoperative examinations up to 3 months post treatment: miscreated flap (1.2%); cells growing under the flap (4.7%); and double vision (or “ghost images”) in the operative eye (8.1%).

The following subjective symptoms were reported as present “often or always” by a higher percentage of subjects 3 months after treatment than before treatment: dryness (22% vs. 6%); and halos (20% vs. 13%).

Important Patient Information

LASIK (laser-assisted in situ keratomileusis) is a laser surgery procedure that permanently changes the shape of the cornea to reduce or eliminate nearsightedness, farsightedness, or mixed visual irregularities due to an abnormal curve in the cornea. Only an eye care professional trained in laser vision correction can determine if you are a candidate for this procedure.

Contraindications: You should not have LASIK if you have collagen vascular (such as rheumatoid arthritis), autoimmune, or an immunodeficiency disease because they affect the body’s ability to heal. You should not have this procedure if you are pregnant or nursing, show signs of corneal thinning, or take medications with eye-related side effects, such as Isotretinoin (Accutane®) for acne treatment or Amiodarone hydrochloride (Cordarone®) for normalizing heart rhythm.

Warnings: LASIK is not recommended if you have diabetes, a history of herpes simplex or herpes zoster keratitis, significant dry eye, or severe allergies.

Precautions: Your doctor will examine your eyes to determine if you are a candidate for this procedure. Talk to your doctor about any eye-related conditions, injuries, or surgeries you have had, as well as any changes to your vision in the past year. These may result in poor vision after LASIK. Tell your doctor about any medications you are taking. After surgery, you may find it more difficult to see in conditions such as dim light, rain, snow, fog, or glare from bright lights at night. LASIK is for patients 21 and over.

Side effects: Possible side effects include dryness, which may be severe; loss of vision or the possible need for glasses or contact lenses after surgery; and visual disturbances such as halos (hazy rings around lights), glare, starbursts, double images, and other visual irregularities that may be debilitating. LASIK requires the use of an instrument (keratome) that cuts a flap on the surface of the cornea, and this may potentially cause swelling, corneal scratch, and other flap-related complications.

Please consult with your eye care professional and carefully review the Patient Information Booklet regarding the potential risks and benefits of this procedure. Results may vary for each individual patient.

Please see additional Important Patient Information.

The iLASIK platform utilizes Advanced CustomVue technology with the Star S4 IR excimer laser system and WaveScan WaveFront system, as well as the IntraLase FS femtosecond laser or iFS advanced femtosecond laser.

Caution: U.S. Federal Law restricts these devices to use by practitioners who have been trained in their calibration and operation and who have experience in the surgical treatment and management of refractive errors.

Menu Title